Allergy Therapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	57.29	55.04	55.2	59.59	72.77	84.33
Revenue Growth (YoY)	2.94%	-0.28%	-7.36%	-18.11%	-13.71%	7.83%
Cost of Revenue	27.38	25.74	25.46	26.34	23.26	22.11
Gross Profit	29.92	29.3	29.74	33.25	49.51	62.23
Selling, General & Admin	42.2	38.61	37.62	49.17	46.96	45.98
Research & Development	16.56	15.38	22.9	20.12	15.66	12.89
Amortization of Goodwill & Intangibles	0.45	0.56	0.53	-	-	-
Other Operating Expenses	-1.06	-1.24	-1.53	-0.86	-0.74	-0.57
Operating Expenses	64.06	57.79	64.07	68.43	61.88	58.3
Operating Income	-34.14	-28.49	-34.34	-35.19	-12.37	3.93
Interest Expense	-6.99	-6.37	-3.79	-2.16	-0.54	-0.39
Interest & Investment Income	0.31	0.38	0.29	0.33	0.25	0.11
Other Non Operating Income (Expenses)	-6.36	-5.16	-0.09	-	0	0.01
EBT Excluding Unusual Items	-47.17	-39.63	-37.93	-37.02	-12.66	3.66
Merger & Restructuring Charges	-	-	-1.24	-	-	-
Other Unusual Items	-	0.43	-	-4.75	-	-
Pretax Income	-47.17	-39.2	-39.17	-41.77	-12.66	3.66
Income Tax Expense	1.01	0.93	-0.55	1.31	1.12	0.77
Net Income	-48.18	-40.13	-38.62	-43.07	-13.78	2.89
Net Income to Common	-48.18	-40.13	-38.62	-43.07	-13.78	2.89
Net Income Growth	-	-	-	-	-	-59.11%
Shares Outstanding (Basic)	4,996	4,766	3,743	670	643	639
Shares Outstanding (Diluted)	4,996	4,766	3,743	670	643	677
Shares Change (YoY)	4.81%	27.33%	458.41%	4.26%	-4.98%	0.47%
EPS (Basic)	-0.01	-0.01	-0.01	-0.06	-0.02	0.00
EPS (Diluted)	-0.01	-0.01	-0.01	-0.06	-0.02	0.00
EPS Growth	-	-	-	-	-	-59.06%
Free Cash Flow	-37.16	-31.37	-35.54	-33.55	-17.06	6.03
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.05	-0.03	0.01
Gross Margin	52.22%	53.23%	53.87%	55.79%	68.03%	73.79%
Operating Margin	-59.58%	-51.75%	-62.20%	-59.05%	-17.00%	4.66%
Profit Margin	-84.08%	-72.91%	-69.97%	-72.28%	-18.93%	3.42%
Free Cash Flow Margin	-64.86%	-57.00%	-64.38%	-56.30%	-23.44%	7.15%
EBITDA	-31.61	-26.18	-32.17	-33.08	-10.24	6.11
EBITDA Margin	-55.16%	-47.56%	-58.27%	-55.51%	-14.07%	7.25%
D&A For EBITDA	2.53	2.31	2.17	2.11	2.13	2.19
EBIT	-34.14	-28.49	-34.34	-35.19	-12.37	3.93
EBIT Margin	-59.58%	-51.75%	-62.20%	-59.05%	-17.00%	4.66%
Effective Tax Rate	-	-	-	-	-	21.08%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.